BioWorld

Nov. 16, 2009

Ziopharm's Bet: Cancer Pills Will Beat I.V.; Off-On Method Intrigues

"Ruthlessly efficient" is how Jonathan Lewis, CEO and chief medical officer of Ziopharm Oncology Inc., last week described his firm's approach to research and financial management. Read More

Money Raised Year to Date

No Public Funds or Partners: Can Istodax Be New Approval Model?

Enzon's Specialty-Biz Offload Leaves Convertible Overhang

Money Raised By Biotech in 2009

Week in Review

Word on the Street

Week in Washington

FDA Approvals for October

Phase I Clinical Trials Update: October 2009

Phase II Clinical Trials Update: October 2009

Pivotal/Phase III Clinical Trials Update: October 2009

American College of Rheumatology

American Association for the Study of Liver Disease

Non-U.S. Clinical Trials And Regulatory Actions: October 2009

FDA Submissions, Approvals And Other Actions: October 2009

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

Ethyreal launches to treat the underlying cause of Graves’, TED

BioWorld

Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...

Microbiota modulates the antidepressant effects of GLP-1 analogues

BioWorld Science

Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...

EHA 2026: With new lenses, a changing view on pediatric cancers

BioWorld

In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...

Microscopic image of chronic myeloid leukemia

Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid

BioWorld

Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...